In the wake of the increase in Current Liabilities in the third quarter 2020, Quick Ratio fell to 0.44 below Cellular Biomedicine Group Inc average.

Within Biotechnology & Pharmaceuticals industry 131 other companies have achieved higher Quick Ratio than Cellular Biomedicine Group Inc in third quarter 2020. While Quick Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 2962 to 3054.

Explain Quick Ratio?
How much Cash & cash equivalents CBMG�s has?
What are CBMG�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CBMG Quick Ratio	(Sep 30 2020) Q3	(Jun 30 2020) Q2	(Mar 31 2020) Q1	(Dec 31 2019) Q4	(Sep 30 2019) Q3
Y / Y Current Liabilities Change	129.33 %	28.33 %	60.23 %	283.87 %	336 %
Y / Y Cash & cash equivalent Change	-10.36 %	-65.8 %	-52.05 %	-67.81 %	-57.25 %
Quick Ratio MRQ	0.44	0.48	0.92	0.72	1.12
CBMG's Total Ranking	# 3054	# 2962	# 474	# 504	# 1977
Seq. Current Liabilities Change	108.41 %	20.91 %	-0.59 %	-8.45 %	16.62 %
Seq. Cash & cash equivalent Change	91.64 %	-37.11 %	27.04 %	-41.45 %	-26.89 %

Quick Ratio third quarter 2020 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 132
Healthcare Sector	# 838
Overall Market	# 3054

Quick Ratio Statistics
High	Average	Low
22.87	5.33	0.03
(Sep 30 2016)		(Jun 30 2012)

Financial Statements
Cellular Biomedicine Group Inc 's Current Liabilities	$ 59 Millions	Visit CBMG's Balance sheet
Cellular Biomedicine Group Inc 's Cash & cash equivalent	$ 26 Millions	Visit CBMG's Balance sheet
Source of CBMG's Sales		Visit CBMG's Sales by Geography

Cumulative Cellular Biomedicine Group Inc 's Quick Ratio

CBMG's Quick Ratio for the trailling 12 Months

CBMG Quick Ratio	(Sep 30 2020) 12 Months	(Jun 30 2020) 12 Months	(Mar 31 2020) 12 Months	(Dec 31 2019) 12 Months	(Sep 30 2019) 12 Months
Y / Y Current Liabilities TTM Growth	95.92 %	107.36 %	201.57 %	290.92 %	251.3 %
Y / Y Cash & cash equivalent TTM Growth	-53.06 %	-60.48 %	-46.48 %	-37.22 %	-5.92 %
Quick Ratio TTM	0.58	0.8	1.13	1.51	2.42
Total Ranking TTM	# 2141	# 1686	# 1303	# 1071	# 671
Seq. Current Liabilities TTM Growth	32.94 %	6.59 %	10.24 %	25.41 %	40.7 %
Seq. Cash & cash equivalent TTM Growth	-3.7 %	-24.34 %	-17.92 %	-21.5 %	-18.93 %

Quick ratio ranking by company, industry and sector >> Back to CBMG Financial Strength Comparisons >> Go to Compare CBMG Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2020 to $59.30 millions, cumulative Quick Ratio decreased to 0.58 below the Cellular Biomedicine Group Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 118 other companies have achieved higher Quick Ratio than Cellular Biomedicine Group Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 1531 to 4591.

Explain Quick Ratio?
How much Cash & cash equivalents CBMG�s has?
What are CBMG�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 119
Healthcare Sector	# 921
Within the Market	# 3054

trailing twelve months Quick Ratio Statistics
High	Average	Low
19.32	4.93	0.1
(Mar 31 2017)		(Sep 30 2012)

Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2020 MRQ Cash & cash equivalent	Sep 30 2020 MRQ Current Liabilities
Orchard Therapeutics Plc	0.99	$ 41.502 Millions	$ 41.851 Millions
Sorrento Therapeutics Inc	0.82	$ 75.176 Millions	$ 92.125 Millions
Outlook Therapeutics Inc	0.79	$ 12.536 Millions	$ 15.889 Millions
Agenus Inc	0.78	$ 114.144 Millions	$ 146.895 Millions
Palisade Bio Inc	0.75	$ 0.751 Millions	$ 1.002 Millions
Titan Pharmaceuticals Inc	0.69	$ 4.073 Millions	$ 5.877 Millions
Champions Oncology Inc	0.67	$ 8.553 Millions	$ 12.754 Millions
Axcella Health Inc	0.64	$ 3.403 Millions	$ 5.281 Millions
Cyclo Therapeutics Inc	0.49	$ 2.238 Millions	$ 4.546 Millions
Acorda Therapeutics Inc	0.46	$ 63.257 Millions	$ 138.749 Millions
Cellular Biomedicine Group Inc	0.44	$ 26.029 Millions	$ 59.297 Millions
Biogen Inc	0.36	$ 1,355.000 Millions	$ 3,804.000 Millions
Protalix Biotherapeutics inc	0.31	$ 13.533 Millions	$ 43.895 Millions
Xtant Medical Holdings Inc	0.29	$ 2.741 Millions	$ 9.331 Millions
Kiromic Biopharma Inc	0.26	$ 0.469 Millions	$ 1.779 Millions
Zeo Scientifix Inc	0.24	$ 0.609 Millions	$ 2.540 Millions
Gene Biotherapeutics Inc	0.16	$ 0.782 Millions	$ 4.927 Millions
Scinai Immunotherapeutics Ltd	0.15	$ 2.930 Millions	$ 19.965 Millions
Qrons Inc	0.12	$ 0.092 Millions	$ 0.793 Millions

Date modified: 2026-09-08T15:10:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.